xCell showed significant enrichment of Th1, Th2, myeloid dendritic cells, macrophages, and T NK cells in low ARID1A mRNA ccRCC with elevation of Tregs in tumors that have high ARID1A.<h4>Conclusion</h4>Low ARID1A expression (protein and mRNA) is a marker of poor prognosis in ccRCC, and is associated with shorter survival and reduced TILs, but immune cells linked to ICI response are increased offering an immune advantage to ARID1A<sup>Low</sup> patients who receive ICI therapy. This evidence concerns the gene ARID1A and nonpapillary renal cell carcinoma.